CORDIS
EU research results

CORDIS

English EN
DC-based immunotherapy to treat Malignant Mesothelioma

DC-based immunotherapy to treat Malignant Mesothelioma

Objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 Gd Rotterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 375 146,94

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA POLITECNICA DELLE MARCHE

Italy

EU Contribution

€ 669 452,73

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 669 451,91

UNIVERSITAIR ZIEKENHUIS ANTWERPEN

Belgium

EU Contribution

€ 668 874,95

UNIVERSITY OF LEICESTER

United Kingdom

EU Contribution

€ 669 215,63

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

France

EU Contribution

€ 659 822,84

EUROPEAN CANCER PATIENT COALITION

Belgium

EU Contribution

€ 23 000

AMPHERA BV

Netherlands

EU Contribution

€ 48 000

Project information

Grant agreement ID: 668769

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 782 965

  • EU contribution

    € 5 782 965

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands